{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:48:10Z","timestamp":1761965290731,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a malignancy with a leading lethality. The etiology is quite diverse, ranging from viral infections to metabolic disorders or intoxications, and associates with specific somatic mutational patterns and specific host immunological phenotypes. Particularly, hepatitis C virus (HCV)-infected liver is featured by an activation of interferon (IFN)-stimulated genes (ISGs; IFN signature), which we suppose is driven by type III IFNL4. Taking advantage of the TCGA collection of HCC patients of various different etiologies, this study aimed at validating our previous findings on hepatic IFNL4 gene activation in HCV infection in an independent and larger cohort of patients with advanced liver disease. In a cohort of n = 377 cases, the entirety of the sequencing data was used to assess the IFNL genotypes, and the cases were stratified for etiology. The number of IFNL4 transcripts within nonmalignant and malignant tissues was found to be more abundant in patients with HCV or HCV\/HBV infections when compared to other risk factors. Moreover, in patients with HCV infection as a risk factor, a close, positive relationship was found between ISG activation and the number of functional IFNL4 transcripts. Data on this independent TCGA sample support the concept of an IFNL4-dependent HCV-driven activation of hepatic ISGs. In addition to that, they add to the understanding of etiology-related host immunological phenotypes in HCC.<\/jats:p>","DOI":"10.3390\/ijms22157803","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T11:53:23Z","timestamp":1626868403000},"page":"7803","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic IFNL4 Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology"],"prefix":"10.3390","volume":"22","author":[{"given":"Henriette","family":"Huschka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, 37075 Goettingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-4538","authenticated-orcid":false,"given":"Sabine","family":"Mihm","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, 37075 Goettingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T.F., Al Lami, F.H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., and Amini, E. (2018). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol., 4, 1553\u20131568.","DOI":"10.1200\/JCO.2018.36.15_suppl.1568"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention","volume":"70","author":"Liu","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3350\/cmh.2015.21.3.220","article-title":"The mutational landscape of hepatocellular carcinoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hep.30212","article-title":"Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma","volume":"69","author":"Inada","year":"2019","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/labinvest.3700135","article-title":"Interferon type I gene expression in chronic hepatitis C","volume":"84","author":"Mihm","year":"2004","journal-title":"Lab. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","article-title":"Hepatitis B virus does not interfere with innate immune responses in the human liver","volume":"154","author":"Suslov","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/JVI.75.3.1332-1338.2001","article-title":"Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: Detection by suppression-subtractive hybridization","volume":"75","author":"Patzwahl","year":"2001","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000369973","article-title":"Activation of type I and type III interferons in chronic hepatitis C","volume":"7","author":"Mihm","year":"2015","journal-title":"J. Innate Immun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Muchmore","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Key, F.M., Peter, B., Dennis, M.Y., Huerta-Sanchez, E., Tang, W., Prokunina-Olsson, L., Nielsen, R., and Andres, A.M. (2014). Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet., 10.","DOI":"10.1371\/journal.pgen.1004681"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Amanzada, A., Kopp, W., Spengler, U., Ramadori, G., and Mihm, S. (2013). Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084026"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/jmv.24763","article-title":"Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients","volume":"89","author":"Murakawa","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/gene.2015.11","article-title":"Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study","volume":"16","author":"Noureddin","year":"2015","journal-title":"Genes Immun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1038\/ncomms6699","article-title":"Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes","volume":"5","author":"Bibert","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/jir.2019.0048","article-title":"What have we learned from studies of IFN-lambda variants and hepatitis C virus infection?","volume":"39","author":"Jackson","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yan, Y., Zheng, L., Du, Q., Cui, X., Dong, K., Guo, Y., and Geller, D.A. (2021). Interferon regulatory factor 1 (IRF-1) downregulates checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in hepatocellular carcinoma (HCC) cells. Br. J. Cancer.","DOI":"10.1038\/s41416-021-01337-6"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00262-020-02586-9","article-title":"Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells","volume":"69","author":"Yan","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2021.03.002","article-title":"Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10\/CXCR3 axis in hepatocellular carcinoma (HCC)","volume":"506","author":"Yan","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Huschka, H., and Mihm, S. (2020). Interferon-lambda (IFNL) germline variations and their significance for HCC and PDAC progression: An analysis of The Cancer Genome Atlas (TCGA) data. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07589-4"},{"key":"ref_25","unstructured":"R Core Team (2021, July 14). R: A Language and Environment for Statistical Computing, Available online: https:\/\/wwwR-projectorg\/."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/15\/7803\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:32:58Z","timestamp":1760164378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/15\/7803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":25,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22157803"],"URL":"https:\/\/doi.org\/10.3390\/ijms22157803","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,7,21]]}}}